Neither screening nor risk-based policies are
perfect. As it is unclear when and for whom PCR testing or vaccination
will be available, it is worth identifying the most effective policy to
protect infants from invasive GBS infections. Currently, the GBS3 trial
is being conducted in the UK.5 Hopefully, there soon
will be clinical data available on effectiveness and cost-effectiveness,
to further help the discourse on this important
topic.